|
Accueil > Actualité
AstraZeneca: green light for Ultomiris in NMOSD in US
(CercleFinance.com) - AstraZeneca announces that Ultomiris (ravulizumab-cwvz) has been approved in the US for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD), a rare and debilitating autoimmune disease affecting the central nervous system, including the spine and optic nerves.
Approval by the US FDA is based on positive results from a Phase III trial, published in Annals of Neurology. Ultomiris met the primary endpoint of time to first relapse in the trial, as confirmed by an independent review committee. No relapses were observed in Ultomiris patients with a median treatment duration of 73 weeks. Copyright (c) 2024 CercleFinance.com. All rights reserved. |
26/04/2024 17:39
bioMérieuxle titre monte, un analyste reste à l'achat 26/04/2024 17:31 Alstomdistingué par le prix Hydrogen Mobility 26/04/2024 17:26 Estée Lauderlaboratoire d'innovation IA avec Microsoft 26/04/2024 17:01 Microsoftlaboratoire d'innovation IA avec Estée Lauder 26/04/2024 16:36 Snaples résultats, pour une fois, surprennent à la hausse 26/04/2024 16:27 MersenAmiral Gestion sous les 5% du capital Tous les articles sociétés |
